INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Aaron Richard Hansen,Thomas S. Stanton,Min-Hee Hong,Ezra E.W. Cohen,Hisham Mehanna,Michael Jon Chisamore,David Turner,Sapna Yadavilli,Kelly Bell,Carlos Baccan,Rosalida Leone,Helen Chen,Helen Zhou,Catherine E. Ellis,Marc S. Ballas,Axel Hoos,Danny Rischin

INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

2020

Aaron Richard Hansen
Thomas S. Stanton
Min-Hee Hong
Ezra E.W. Cohen
Hisham Mehanna
Michael Jon Chisamore
David Turner
Sapna Yadavilli
Kelly Bell
Carlos Baccan
Rosalida Leone
Helen Chen
Helen Zhou
Catherine E. Ellis
Marc S. Ballas
Axel Hoos
Danny Rischin

TPS6591Background: Pembrolizumab as part of first-line treatment for patients (pts) with R/M HNSCC has improved survival. However, in order to further improve outcomes in this population investigat...

Keywords:

Gastroenterology
first line treatment
Head and neck squamous-cell carcinoma
Agonist
Pathology
PD-L1 Positive
Pembrolizumab
Internal medicine
Antibody
Placebo
T cell
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations